Ireland Joins Beneluxa Initiative To Improve Access To New Medicines

Ireland Joins Beneluxa Initiative To Improve Access To New Medicines The beneluxa initiative is a collaboration between belgium, the netherlands, austria, luxembourg and ireland. the collaboration aims for sustainable access to, and appropriate use of, medicines in the participating countries, and to increase patients’ access to high quality affordable treatments. Access to this treatment has been made possible through ireland’s participation in the beneluxa initiative, a collaboration between belgium, the netherlands, luxembourg, austria, and ireland.

Taskforce Of The Beneluxa Initiative Publishes Pharmaceutical World's most expensive drug approved for use in ireland. updated wednesday, 24 jan 2024 14:44. the original price of the drug for the one off dose was €2.8m (stock image) by fergal bowers. 27 jun 2018, 9:39 am. patients in ireland should benefit from speedier access to innovative new drugs as a result of the country joining the beneluxa initiative on pharmaceutical policy, life sciences experts have said. in the eu, member states are responsible for setting their own policies on pricing and reimbursement of medicines. When it comes to cancer medicines, the situation is even worse. just 20% of new cancer medicines launched in 2014 15 were available in ireland by the end of 2016, compared to 28% for belgium, 60% for the netherlands and 76% for austria. in other words, we lag the same countries in the group the government wants us to join. The beneluxa initiative aims to improve patient access to innovative drugs in belgium, the netherlands, luxemburg, austria and now ireland, while maintaining affordable prices. this is done by conducting joint horizon scanning for new medicines, sharing policy information and expertise, mutually recognising health technology assessments and.

International Agreement Aimed At Securing Affordable And Timely Access When it comes to cancer medicines, the situation is even worse. just 20% of new cancer medicines launched in 2014 15 were available in ireland by the end of 2016, compared to 28% for belgium, 60% for the netherlands and 76% for austria. in other words, we lag the same countries in the group the government wants us to join. The beneluxa initiative aims to improve patient access to innovative drugs in belgium, the netherlands, luxemburg, austria and now ireland, while maintaining affordable prices. this is done by conducting joint horizon scanning for new medicines, sharing policy information and expertise, mutually recognising health technology assessments and. Finally, through ireland’s participation in the beneluxa initiative, a collaboration between belgium, the netherlands, luxembourg, austria, and ireland, atidasagene autotemcel (libmeldy®) was approved to treat metachromatic leukodystrophy (mld). mld is a rare genetic disease and libmeldy is a one time therapy designed to correct this gene. The beneluxa ministers responsible for pharmaceutical policy welcomed ireland joining and participating in the collaboration. dutch minister bruno bruins for medical care said: “ireland is a great addition to the beneluxa family. all five countries face similar issues regarding access and affordability to new and innovative medicines. by.